YSPSL for Prevention of Delayed Graft Function Part B
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced
kidney injury and resultant delayed graft function (DGF). PSGL-1 is a ligand for P-, E-, and
L-selectin. It has been reported that YSPSL (rPSGL-Ig) blocks P-selectin and, to a lesser
degree, E- and L-selectin. Both sPSGL-1 and YSPSL (rPSGL-Ig) have been shown in animal models
to reduce both cytokines and tissue damage associated with ischemia reperfusion and to
improve renal function post-transplant. Therefore, the current phase I/II clinical study is
designed to assess the safety and efficacy of YSPSL (rPSGL-Ig) in preventing DGF in patients
undergoing cadaveric kidney transplants and to determine a dose for future pivotal studies.